An investigation for investors in Ophthotech Corp (NASDAQ:OPHT) shares over potential securities laws violations by Ophthotech was announced and ASDAQ:OPHT stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 12/19/2016 -- An investigation was announced for investors of Ophthotech Corp over potential securities laws violations by Ophthotech in connection certain financial statements.
Investors who purchased shares of Ophthotech Corp (NASDAQ:OPHT), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Ophthotech Corp regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On December 12, 2106, Ophthotech Corp (NASDAQ:OPHT) announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Lucentis® (ranibizumab) anti-VEGF therapy compared to Lucentis® monotherapy for the treatment of wet age-related macular degeneration (AMD). Ophthotech Corp also said that the addition of Fovista® to a monthly Lucentis® regimen did not result in benefit as measured by the mean change in visual acuity at the 12 month time point. Shares of Ophthotech Corp (NASDAQ:OPHT) declined to as low as $4.53 per share on December 15, 2016.
On December 16, 2016, NASDAQ:OPHT shares closed at $5.19 per share.
Those who purchased shares of Ophthotech Corp have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego